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Piloting the United Kingdom ‘Prescribing Safety Assessment’ with Pharmacist 
Prescribers in Scotland 
 
Abstract  
Background 
Prescribing is a complex task requiring considerable knowledge and skills. The Prescribing 
Safety Assessment (PSA) was developed by the British Pharmacological Society and the 
United Kingdom (UK) Medical Schools Council.  Between February and June 2014, over 
7,000 final year medical students undertook the PSA, with an overall pass rate of 94%. 
Independent prescribing for suitably trained pharmacists was introduced in the UK in 
2006. To date there has been little focus on any objective measures of the prescribing 
safety.  
Objective 
To determine the PSA performance of a pilot group of pharmacist prescribers in Scotland 
relative to medical students and to test the feasibility and acceptability of running the 
PSA. 
Methods 
A group of 59 pharmacist prescribers took part in ten events. The PSA consisted of 30 
questions to be completed over 60 minutes. All questions had been used in the 2014 
assessments for final year medical students. The PSA was undertaken online under 
invigilated conditions, mirroring the medical student assessment. One month later, 
participants were invited to complete an online evaluation questionnaire.  
Results 
The mean overall PSA scores (±SD) were 87.5%±8.7 (range 52-98) compared to a 
88.5% for medical students. Based on an Angoff passmark of 76.0%, 53 pharmacists 
(89.8%) passed compared to an overall pass rate in PSA 2014 of 94%. Pharmacists 
performed equivalently to medical students in all assessment areas, with a slightly lower 
performance in the prescribing, drug monitoring and data interpretation questions offset 
by better performance in prescription review and adverse drug reactions. Feedback was 
positive in relation to appropriateness, relevance and level of difficulty of the PSA 
although several commented that they were practicing in very specific clinical areas.  
Conclusion 
These pilot events have benchmarked the PSA performance of pharmacist prescribers 
with final year medical students, and feedback confirmed feasibility and acceptability. 
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Introduction  
Prescribing is a complex and challenging task requiring considerable knowledge and 
skills, as evidenced by the ten principles of good prescribing defined by the British 
Pharmacological Society (BPS, Box 1).  
 
 
Box 1. Ten principles of good prescribing, British Pharmacological Society.1 
1. Be clear about the reasons for prescribing 
2. Take into account the patient’s medicines history before prescribing 
3. Take into account other factors that might alter the benefits and risks of 
treatment 
4. Take into account the patient’s ideas, concerns and expectations 
5. Select effective, safe and cost-effective medicines individualized for the patient 
6. Adhere to national guidelines and local formularies where appropriate 
7. Write unambiguous legal prescriptions using the correct documentation 
8. Monitor the beneficial and adverse effects of medicines  
9. Communicate and document prescribing decisions and the reasons for them 
10.  Prescribe within the limits of your knowledge, skills and competence. 
 
The demands on prescribers have multiplied in recent years due to many factors 
including more complicated medicines regimens, combined with increasing prescribing 
prevalence. Scottish prescribing data from 2014 highlighted that 20.8% of patients with 
two clinical conditions were prescribed four to nine medicines, and 10.1% prescribed ten 
or more medicines; in patients with six or more comorbidities, these values increased to 
47.7% and 41.7% respectively.2 These data highlight even more the need for highly 
knowledgeable and skilled prescribers to ensure that all ten of the BPS principles are 
met.  
  
There is, however, a vast accumulation of evidence of widespread suboptimal prescribing 
leading to potential patient care and safety issues. In a systematic review of prescribing 
errors by junior doctors, Ross et al. found errors prevalent in 2–514 per 1000 items 
prescribed and 4–82% of patients or charts reviewed.3 In a later systematic review of all 
prescribing errors in hospital inpatients, Lewis et al. reported 52 (8–227) errors per 100 
admissions and 24 (6–212) errors per 1000 patient days.4 A recent study of junior doctor 
prescribing in hospitals in Scotland identified an error rate of 36% (1700/4710) of patient 
prescription charts and 7.5% (3364/44726) of items prescribed.5 
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Given these statistics, assessing competence in prescribing is crucial within a framework 
of clinical governance and promoting patient safety.6 Given the widespread evidence of 
suboptimal prescribing, The Prescribing Safety Assessment (PSA) was developed by the 
BPS and the United Kingdom (UK) Medical Schools Council.7 The PSA assesses 
prescribing skills based on the competencies identified by the UK General Medical Council 
and outlined in ‘Outcomes for Graduates’, which sets out the knowledge, skills and 
behaviors that new UK medical graduates must be able to show.8 These prescribing 
competencies are: writing new prescriptions; reviewing existing prescriptions; calculating 
drug doses; identifying and avoiding both adverse drug reactions and medication errors; 
and amending prescribing to suit individual patient circumstances.  
 
The PSA is designed to allow final year UK medical students to demonstrate that they 
have the necessary knowledge, skills and judgment (in relation to the safe and effective 
use of medicines) to begin their work as junior prescribers in National Health Services 
(NHS) hospitals in the UK. It is an open book assessment taken under time limited 
restrictions, with candidates having access to the British National Formulary (BNF). The 
PSA is delivered online from a ‘cloud-based’ server and comprises eight sections 
containing question styles that cover different aspects of the clinical activity undertaken 
by prescribers (Figure 1). Questions are set in any one of seven different clinical settings 
of medicine (med), surgery (surg), old people (eld), pediatrics (ped), psychiatry (psych), 
obstetrics and gynecology (O&G) and general practice (GP). 
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Figure 1. The standard structure of the Prescribing Safety Assessment. 
 
The PSA has been piloted in UK medical schools over several years but was implemented 
widely for the first time in 2014 (PSA 2014).9 Between February and June 2014, over 
seven thousand final year medical students undertook the PSA, with an overall pass rate 
of 94%. This process has been repeated again in 2015 and now also includes medical 
schools in Ireland and Malta. As the PSA has been introduced relatively recently, no 
studies to date have provided evidence of impact on prescribing safety in practice and 
the prevalence and severity of prescribing errors. However, many medical students have 
commented that the experience of preparing with online practice papers and participation 
in the assessment had engendered an enhanced sense of confidence about their future 
prescribing of drugs.9 
 
Prescribing is no longer solely within the province of doctors hence there is a need to 
consider prescribing competence and safety of wider groups of health professionals. Key 
developments in prescribing policy and practice have been implemented in the UK with 
the introduction of prescribing rights for a range of healthcare professionals. For 
pharmacists, supplementary prescribing was introduced in 2003, and extended to 
independent prescribing in 2006.10 Supplementary prescribing (SP) is defined as 
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‘voluntary partnership between an independent prescriber (doctor or dentist) and a 
supplementary prescriber to implement an agreed patient-specific clinical management 
plan (CMP) with the patient’s agreement’. While developing the CMP and obtaining 
agreement were found to be cumbersome, independent prescribing (IP) is a more 
autonomous model of prescribing, defined as ‘prescribing by a practitioner responsible 
and accountable for the assessment of patients with undiagnosed or diagnosed conditions 
and for decisions about clinical management required, including prescribing’.11 There are 
no restrictions on the medical conditions managed or drugs prescribed by either 
supplementary or independent prescribers. 
 
Those entering the IP training programme (which has superseded SP programme) must 
have at least two years’ patient facing experience as a pharmacist, and provide evidence 
that there is a patient need for pharmacist prescribing in their place of employment. The 
course is accredited by the General Pharmaceutical Council (GPhC) and comprises two 
main components: a university component equivalent to 26 days of full-time education; 
and period of learning in practice (PLP), under the direction of a designated medical 
practitioner, of a minimum of 12 days.12 Both components must be passed prior to 
registration as a prescriber with GPhC. While assessment methods are varied and include 
written assessments, objective structured clinical examinations (OSCEs) and submission 
of a portfolio of evidence, there is no specific assessment of prescribing safety. Given 
that the use of the PSA within medical schools in the UK is increasing, and that IPs have 
the same prescribing rights as doctors, there is a need to benchmark their prescribing 
safety.    
 
The aims of this research were to determine the PSA performance of a pilot group of 
pharmacist prescribers in Scotland relative to medical students and to test the feasibility 
and acceptability of running the PSA.  
 
 
Method 
PSA development 
The PSA used for this pilot consisted of 30 questions to be completed over 60 minutes. 
All questions had been used in the 2014 round of assessments for final year medical 
students in 31 UK medical schools and standard set using a modified Angoff procedure 
(procedure for setting a criterion-referenced passing point), as per the medical student 
assessment.9 Questions were mapped to the eight areas of: prescribing; prescription 
review; planning management; providing information; calculation skills; adverse drug 
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reactions; drug monitoring; and data interpretation. Further detail of these areas is 
provided in Table 1. 
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Table 1 – Details of PSA question areas in terms of reasoning and judgement, and measurable action.7 
Question Area Reasoning and Judgement Measurable Action 
Prescribing Deciding on the most appropriate prescription (drug, 
dose, route and frequency) to write based on the clinical 
circumstances and supplementary information 
Writing a safe, effective and legal prescription for 
medicines using the documentation provided to tackle 
specific indications highlighted by the question 
Prescription 
review 
Deciding which components of the current prescription 
list are inappropriate, unsafe or ineffective for a patient 
based on their clinical circumstances 
Identifying prescriptions (drugs, doses or routes) that 
are inappropriate, unsafe or ineffective from amongst 
the current list of prescribed medicines 
Planning Deciding which combination of therapies would be most Selecting the most appropriate combination of treatment 
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management appropriate to manage a particular clinical situation strategies based on individual patient circumstances 
Providing 
information 
Deciding what are the important bits of information that 
should be provided to patients to allow them to choose 
whether to take the medicine and to enhance its safety 
and effectiveness 
Selecting the information that is most appropriate 
Calculation skills Making an accurate drug dosage calculation based on 
numerical information 
Recording the answer accurately with appropriate units 
of measurement 
Adverse drug 
reactions 
Identifying likely adverse reactions of specific drugs, 
drugs that are likely to be causing specific adverse drug 
reactions, potentially dangerous drug interactions and 
deciding on the best approach to managing a clinical 
presentation that results from the adverse effects of a 
drug 
Selecting likely adverse reactions of specific drugs, 
selecting drugs to discontinue as likely causes of specific 
reactions, avoiding potential drug-interactions and 
providing appropriate treatment for patients suffering an 
adverse event 
Drug monitoring Deciding on how to monitor the beneficial and harmful 
effects of medicines. 
Identifying the appropriate methods of assessing the 
success or failure of a therapeutic intervention. 
Data 
interpretation   
Deciding on the meaning of the results of investigations 
as they relate to decisions about on-going drug therapy 
Making an appropriate change to a prescription based on 
those data 
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The distribution of the diagnoses and settings of the clinical case scenarios are illustrated 
in Table 2. 
 
Table 2 - Distribution of the cases included in the PSA, according to primary diagnostic 
category and clinical setting 
Diagnostic 
category 
Number 
of 
questions 
Clinical setting Number 
of 
questions 
Gastroenterology 2 Medicine 8 
Cardiovascular 6 Surgery 2 
Respiratory 3 Elderly care 2 
Neurology 3 Paediatrics 4 
Psychiatry 2 Psychiatry 2 
Infection 3 Obstetrics & 
Gynaecology 
4 
Endocrinology 3 General practice 8 
Rheumatology 2 Total 30 
Anaemia 1 
Contraception 1 
Pregnancy 1 
Dermatology 1 
Metabolic 1 
Overdose 1 
Total 30 
 
Recruitment 
NHS Education for Scotland (NES) is an education and training body within Scotland with 
responsibility of developing and delivering education and training for the healthcare 
workforce. NES maintains an up-to-date database of all pharmacist prescribers and those 
in training in Scotland. An invitation email was sent out to all 744, with 102 noting 
interest in participating; they were invited to participate in ten PSA events planned in 
NES locations in Scotland (Glasgow (5 events), Edinburgh (3 events), Aberdeen (2 
events)). Participants were registered on the PSA online system, which allowed access to 
PSA information and practice materials of three 1-hour test papers and a recorded 
presentation explaining the format of the assessment and how to use the online 
assessment. These processes mirrored those of the medical students.  
 
Assessment 
Approximately one month following registration, participants attended the event closest 
to their practice bases. Each completed a brief demographic questionnaire of current 
prescribing status, years registered as pharmacist and prescriber, and main practice 
setting. The PSA was undertaken online under invigilated conditions, with access to the 
online BNF, mirroring the medical student assessment.   
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Evaluation 
One month following the PSA, participants were invited to complete an online evaluation 
questionnaire comprising ten Likert type items (strongly agree to strongly disagree) and 
ten items rating self-confidence in prescribing abilities (scale of 0, ‘not confident’ to 10, 
‘highly confident’). In addition, space was provided for free text comments on any aspect 
of the PSA. The items were developed by a member of the research team and reviewed 
by the others in terms of face and content validity. Data were analysed using descriptive 
statistics. Thematic content analysis was performed independently on the responses to 
free text comments by two members of the research team. Consensus was achieved 
without having to involve any others.  
 
Figure 1 summarises the timeline of the key steps involved.  
 
PSA 
developed
Pharmacist 
prescribers 
recruited
Participants 
registered, 
practice 
sessions
One  month 
later, PSA 
undertaken
One month 
later, 
evaluation 
completed
 
Figure 1 – the timeline of the PSA and evaluation 
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Results 
Participants 
Sixty-nine of the 102 (69.6%) interested were able to attend one of the ten events. Due 
to technical difficulties during one event, 10 were unable to complete the PSA hence data 
are provided for 59 participants. Of these, 42 (71.2%) were actively prescribing, 52 
(88.2%) had been registered as pharmacists more than ten years, 31 (52.5%) had been 
registered prescribers for more than five years, and half (29, 49.2%) worked in primary 
care medical practices.  
 
Candidate performance 
The mean scores (+SD) and range of performance for the PSA overall, and for each of 
the eight areas are illustrated in Table 3.  
Table 3 – Participant PSA performance, N=59 
 
Areas Available 
marks 
Mean 
scores 
+ SD 
Range Mean PSA 
2014, 
medical 
students 
Prescription 
writing 
40 36.6 + 4.9 19 - 40 37.1 
Prescription 
review 
16 15.0 + 1.4 11 - 16  14.3 
Planning 
management 
8 6.1 + 1.4 4 - 8  6.2 
Providing 
information 
6 5.4 + 1.0 2 - 6  5.6 
Dose 
calculations 
8 7.2 + 1.7 0* - 8 7.5 
Adverse drug 
reactions 
8 7.7 + 0.9 4 - 8 7.5 
Drug 
monitoring 
8 5.6 + 1.6 2 - 8 5.9 
Data 
interpretation 
6 3.7 + 1.7 0* - 6 4.5 
Total 
 
100 87.5 + 8.7 52 - 98 88.5 
(*note, the one participant scoring 0 in several areas misunderstood the instructions and 
answered only those questions related directly to the area of prescribing practice) 
 
The mean score for the participants was 87.5 + 8.7% (range 52 - 98) compared to a 
mean score of 88.5% achieved by the final year medical students for the same 
assessment items in PSA 2014. The standard setting of the questions used for final year 
medical students suggested a pass mark for the assessment of 76.0%. Based on that cut 
off score, 53 participants (89.8%) passed compared to an overall pass rate in PSA 2014 
of 94%. Analysis by section suggested that the participants performed equivalently to 
final year medical students in almost all areas, with a slightly lower performance in the 
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prescribing, drug monitoring and data interpretation items offset by better performance 
in prescription review and adverse drug reaction items. 
 
Candidate feedback 
Responses to the evaluation items are given in Table 4, indicating favourable views on 
the appropriateness of the approach, the quality of the presentation and questions and 
the usability of the online interface.  
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Table 4 – Responses to evaluation items, n (N=59) (*some did not complete all items) 
Items  
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The questions in the 
assessment were clear and 
unambiguous 
0 3 7 43 6 4 
*The questions were of a 
reasonable level of difficulty 
0 2 1 41 13 4 
The layout and presentation 
of the questions was easy to 
follow 
0 0 2 27 30 5 
The time provided for 
answering the questions was 
sufficient 
3 9 3 29 15 4 
*The online assessment was 
easy to use 
0 1 1 28 27 4 
The information about the 
PSA (available prior to the 
event on psapilot.net) was 
helpful 
0 0 3 19 37 5 
*The assessment is a suitable 
method to test pharmacist 
prescribers’ knowledge 
0 7 8 33 9 4 
*The assessment is a suitable 
test of prescribing skills 
expected of a pharmacist 
prescriber 
0 3 5 43 6 4 
*The assessment is a suitable 
method to test pharmacist 
prescribers’ competence 
0 5 10 34 8 4 
My prescribing course 
prepared me for the content 
of the questions in this 
assessment 
3 25 14 17 0 3 
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Responses to the items on confidence are given in Table 5, demonstrating very high 
confidence in all aspects of prescribing.  
 
Table 5 – Responses to confidence items, n (N=57, two did not complete this part of the 
questionnaire)  
Items ≤7 8 9 10 N/A Median 
I can write a safe, effective and legal 
prescription 
1 5 24 24 3 9 
I can decide upon the most appropriate 
prescription for my patients (drug, dose, 
form, route) 
0 15 25 15 2 9 
I can identify inappropriate, unsafe or 
ineffective prescribing 
1 6 34 15 1 9 
I can select appropriate condition 
management options for my patients 
5 21 20 10 1 9 
I can clearly communicate necessary 
information to my patients 
2 8 24 23 0 9 
I can carry out therapeutic drug 
monitoring 
13 8 15 15 6 9 
I can avoid potential drug interactions 3 13 29 12 0 9 
I can spot potentially important errors in 
prescribing 
0 7 31 19 0 9 
I can carry out any clinical calculations 
necessary 
5 7 20 25 0 9 
Overall, I feel confident practising as an 
independent prescriber 
2 14 23 14 4 9 
(0, ‘not confident’ to 10, ‘highly confident’) 
 
Content analysis of textual responses identified positive comments that undertaking the 
PSA confirmed their competence and increased their confidence, and that it was suitable 
for all pharmacists and not just prescribers. Several commented that the PSA could be 
incorporated at the start of the prescribing course to give a baseline measure. A few 
noted that the PSA focused on information retrieval from the BNF rather than prescribing 
competence, which should include aspects of patient consultation skills. Several from 
primary care settings commented on the secondary care focus of the assessment 
questions and also that the assessment should be targeted to their specific areas of 
prescribing practice.  
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Discussion 
This study has demonstrated that the overall performance and pass rate of the 
pharmacist prescribers in this pilot was remarkably similar to that of graduating medical 
students exposed to the same questions. The PSA was also found to be feasible and 
acceptable to pharmacist prescribers. 
 
To our knowledge this is the first study which has used the PSA in a group of pharmacist 
prescribers. However, there are several limitations and hence the results should be 
interpreted with caution. The study sample size was limited and the participants a self-
selected group hence there are potential issues of recruitment bias which impacts the 
generalisability of the findings to the population of pharmacist prescribers in Scotland 
and beyond. Indeed, the demographics of the participants shows this to be a relatively 
experienced group of pharmacist prescribers. One further limitation is that data from a 
group of individuals with no actual prescribing experience (final year medical students) 
were compared to registered, experienced pharmacist prescribers. It may be more 
appropriate to compare the outcomes to a group of equally experienced medical 
prescribers.   
 
There is a vast accumulation of expertise around the utility of the PSA in all medical 
schools in the UK in 2014 and extended into Ireland and Malta in 2015. The PSA process 
of question development is robust with input from item authors, editors, peer reviewers, 
standard setters and psychometric support.9 While it is accepted that performance in an 
online prescribing assessment may not relate to prescribing practice and that there are 
no data of improved patient outcomes and safer care, there is little doubt that 
implementing the PSA in final year medical students can facilitate raising and unifying 
prescribing standards. As noted previously, many medical students have commented that 
the experience of preparing for and undertaking the PSA has increased their confidence 
about their future prescribing. It therefore seems appropriate that pharmacist prescribers 
(and indeed all prescribers) are subjected to the same assessment as part of their 
training. This seems all the more relevant given that the National Prescribing Centre 
(now part of the National Institute for Health and Clinical Excellence) has produced a 
single competency framework for all prescribers.13 Patient safety is an overarching theme 
of the competencies within a framework of the patient consultation, prescribing 
effectively and prescribing in context. 
 
The overall performance and pass rate of the participants was similar to that of the 
medical students who had been exposed to the same questions in PSA2014. Importantly, 
the cut-off pass mark score for the participants was set at exactly the same level as for 
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the final year medical students to permit comparison and benchmarking. The questions 
covered a spectrum of clinical settings and while many pharmacist prescribers are likely 
to be practicing within defined therapeutic areas, they are expected to be able to review 
the clinical appropriateness of their patients’ entire medicines regimens. The performance 
is therefore encouraging and should provide confidence in the pharmacists’ prescribing 
skills. While no inferential statistical analysis was conducted, the participants slightly 
better performance in prescription review and writing may reflect their medicines related 
training and clinical experience. Similarly, the lower scores in patient monitoring and 
data interpretation may reflect lesser training and experience in these areas, which may 
improve over time.  However, it must be acknowledged that there were some instances 
of poorer performance in the PSA with six participants not achieving the pass mark; this 
merits further exploration.  Overall performance also appeared to be in line with the 
participants’ self-ratings of their confidence in prescribing, providing evidence of the 
validity of their self-ratings.  
 
The PSA was also found to be feasible and acceptable with only a few participants 
disagreeing with statements on question clarity and ambiguity, time allowed and ease of 
use. Importantly, the majority agreed that the PSA was an appropriate test of prescribing 
knowledge, skills and competence. Interestingly, around half disagreed that their 
prescribing course prepared them adequately in terms of the content of the questions. 
However, the prescribing course does not focus greatly on therapeutics as all 
pharmacists are expected to possess in-depth knowledge, understanding and application. 
Rather, the course focuses more on processes of prescribing around consultation skills, 
shared decision making, team working and governance.12 It may be that incorporating 
the PSA as a compulsory element of the course would provide some evidence of ability in 
aspects of therapeutics.  
 
While a number of studies on UK pharmacist prescribing have researched aspects such as 
the experiences of patients, the general public and other members of the healthcare 
team, generating very positive findings,14-19 there has been little focus on any objective 
measures of prescribing safety. In one very small study in three hospitals in England, 
pharmacists prescribed 680 from 5274 items, noting an error rate of 0.3%.20 While this is 
a positive outcome, there is a need for further research to confirm prescribing safety. 
Pharmacist prescribing is a key strategic area for development supported by the Scottish 
Government. In 2013, the Scottish Government published their Vision and Action plan, ‘A 
Prescription for Excellence’ which states that all pharmacists with a patient facing role 
should be NHS accredited clinical pharmacist independent prescribers managing 
caseloads of patients by 2023.21 Implementing the PSA for all pharmacist prescribers will 
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increase confidence amongst patients and other members of the healthcare team in the 
skills of these prescribers. Research which provides evidence of the internal and external 
validity of the PSA as an actual measure of prescribing safety is therefore warranted.   
 
There is merit in extending the PSA across a larger and more representative group of 
pharmacist prescribers and embedding it within the pharmacist independent prescribing 
course. While this study was based in Scotland, there are clear implications for all 
countries in which prescribing by pharmacists has been implemented and those in which 
pharmacist prescribing is part of the strategic direction of the profession and health 
service.  
 
Conclusion 
These pilot events have benchmarked the PSA performance of pharmacist prescribers 
with final year medical students and feedback confirmed feasibility and acceptability. The 
PSA may be a useful test of pharmacist prescribers’ skills and safe prescribing and should 
be considered further as an element of the prescribing course.  
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Piloting the United Kingdom ‘Prescribing Safety Assessment’ with Pharmacist 
Prescribers in Scotland 
 
Highlights 
This study reports the performance of a pilot group of 59 pharmacist prescribers in 
Scotland undertaking the Prescribing Safety Assessment (PSA) of the British 
Pharmacological Society and the United Kingdom Medical Schools Council. The PSA 
consisted of 30 questions to be completed over 60 minutes. The mean overall PSA scores 
(±SD) were 87.5%±8.7 (range 52-98) compared to a mean score of 88.5% for medical 
students in 2014. This pilot has benchmarked the PSA performance of pharmacist 
prescribers with final year medical students, and feedback confirmed feasibility and 
acceptability. 
 
 
 
 
